Literature DB >> 11040853

Prevalence, pathophysiology, and treatment of patients with asthma and gastroesophageal reflux disease.

J A Alexander1, L W Hunt, A M Patel.   

Abstract

About one third of the US adult population experiences symptoms of gastroesophageal reflux on a monthly basis. Asthma is present in about 5% of the same population. This article reviews and summarizes the literature in the following areas: (1) prevalence of gastroesophageal reflux disease (GERD) in asthmatic patients based on clinical symptoms, endoscopic esophagitis, and 24-hour ambulatory esophageal pH recordings; (2) proposed pathophysiologic mechanisms linking the 2 diseases; and (3) medical and surgical treatment trial results of antireflux therapy for asthmatic patients. Asthmatic patients appear to have an increased prevalence of GERD symptoms and 24-hour esophageal acid exposure. The clinical management of these patients remains controversial. Common management approaches to GERD in asthmatic patients include medical therapy with a proton pump inhibitor and/or antireflux surgery, which improve asthma symptoms in many patients but minimally affect pulmonary function.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11040853     DOI: 10.4065/75.10.1055

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  2 in total

Review 1.  Exacerbations of COPD and symptoms of gastroesophageal reflux: a systematic review and meta-analysis.

Authors:  Thiago Mamôru Sakae; Márcia Margaret Menezes Pizzichini; Paulo José Zimermann Teixeira; Rosemeri Maurici da Silva; Daisson José Trevisol; Emilio Pizzichini
Journal:  J Bras Pneumol       Date:  2013 May-Jun       Impact factor: 2.624

2.  Association between chronic obstructive pulmonary disease and gastroesophageal reflux disease: a national cross-sectional cohort study.

Authors:  Jinhee Kim; Jin Hwa Lee; Yuri Kim; Kyungjoo Kim; Yeon-Mok Oh; Kwang Ha Yoo; Chin Kook Rhee; Hyoung Kyu Yoon; Young Sam Kim; Yong Bum Park; Sei Won Lee; Sang Do Lee
Journal:  BMC Pulm Med       Date:  2013-08-09       Impact factor: 3.317

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.